Research & KnowledgeEvent: September 2, 2026
nference published a peer-reviewed observational study exploring whether every patient needs the highest tolerated GLP-1 dose, examining de-identified healthcare outcomes from patients on semaglutide or tirzepatide.
Published
Signal category
Research & Knowledge
Quote
“In the newly-published peer-reviewed observational study, our team explored the question -- 'Does every patient need the highest tolerated GLP-1 dose?'”
— Venky Soundararajan, Ph.D.|nference team
Company
nference
Making biomedical knowledge computable
- Industry
- Biotechnology Research
- Location
- Cambridge, US
- Company size
- 313 employees
nference leverages the top academic minds, world-class researchers, and real-time access to multimodal, patient-level data to accelerate drug development innovation, generate evidence, and improve clinical trial processes. nSights, our flagship software platform, delivers the most comprehensive biological and clinical insights into patient care.
Founded 2013